Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late‐onset Alzheimer's disease

M. L. Peacock, Daniel L Murman, A. A.F. Sima, J. T. Warren, A. D. Roses, J. K. Fink

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Amyloid plaques in Alzheimer's disease contain β‐amyloid, encoded by portions of exons 16 and 17 of the amyloid precursor protein. The specific association of rare amyloid precursor protein mutations with some kindreds with early‐onset familial Alzheimer's disease suggests that specific abnormalities in amyloid precursor protein may contribute to the pathogenesis of Alzheimer's disease. Until now, there has been no evidence suggesting that amyloid precursor protein mutations could be involved in late‐onset or sporadic Alzheimer's disease. We used reverse transcription–polymerase chain reaction, denaturing gradient gel electrophoresis, and direct DNA sequencing to analyze amyloid precursor protein exons 16 and 17 from postmortem cerebellar samples from patients with histologically confirmed Alzheimer's disease and control subjects. We found a novel point mutation, substitution of cytosine for guanine, at nucleotide 2119 (amyloid precursor protein 770 messenger RNA transcript) in a patient with late‐onset Alzheimer's disease. This substitution deletes a BglII site and substitutes aspartate for glutamine at codon 665. Denaturing gradient gel electrophoresis analysis showed that this mutation was absent in 40 control subjects and 127 dementia patients. Whether this mutation is a rare but normal variant or contributes to the development of Alzheimer's disease is not known. The BglII restriction fragment length polymorphism enables investigators to determine the frequency of this polymorphism in normal subjects and Alzheimer's disease patients.

Original languageEnglish (US)
Pages (from-to)432-438
Number of pages7
JournalAnnals of Neurology
Volume35
Issue number4
DOIs
StatePublished - Jan 1 1994

Fingerprint

Amyloid beta-Protein Precursor
Codon
Alzheimer Disease
Mutation
Genes
Denaturing Gradient Gel Electrophoresis
Exons
Guanine Nucleotides
Cytosine
Amyloid Plaques
Glutamine
DNA Sequence Analysis
Point Mutation
Amyloid
Aspartic Acid
Restriction Fragment Length Polymorphisms
Dementia
Research Personnel
Messenger RNA

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late‐onset Alzheimer's disease. / Peacock, M. L.; Murman, Daniel L; Sima, A. A.F.; Warren, J. T.; Roses, A. D.; Fink, J. K.

In: Annals of Neurology, Vol. 35, No. 4, 01.01.1994, p. 432-438.

Research output: Contribution to journalArticle

Peacock, M. L. ; Murman, Daniel L ; Sima, A. A.F. ; Warren, J. T. ; Roses, A. D. ; Fink, J. K. / Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late‐onset Alzheimer's disease. In: Annals of Neurology. 1994 ; Vol. 35, No. 4. pp. 432-438.
@article{bb18be8f1a0c45b1a7930f0a65fb49a2,
title = "Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late‐onset Alzheimer's disease",
abstract = "Amyloid plaques in Alzheimer's disease contain β‐amyloid, encoded by portions of exons 16 and 17 of the amyloid precursor protein. The specific association of rare amyloid precursor protein mutations with some kindreds with early‐onset familial Alzheimer's disease suggests that specific abnormalities in amyloid precursor protein may contribute to the pathogenesis of Alzheimer's disease. Until now, there has been no evidence suggesting that amyloid precursor protein mutations could be involved in late‐onset or sporadic Alzheimer's disease. We used reverse transcription–polymerase chain reaction, denaturing gradient gel electrophoresis, and direct DNA sequencing to analyze amyloid precursor protein exons 16 and 17 from postmortem cerebellar samples from patients with histologically confirmed Alzheimer's disease and control subjects. We found a novel point mutation, substitution of cytosine for guanine, at nucleotide 2119 (amyloid precursor protein 770 messenger RNA transcript) in a patient with late‐onset Alzheimer's disease. This substitution deletes a BglII site and substitutes aspartate for glutamine at codon 665. Denaturing gradient gel electrophoresis analysis showed that this mutation was absent in 40 control subjects and 127 dementia patients. Whether this mutation is a rare but normal variant or contributes to the development of Alzheimer's disease is not known. The BglII restriction fragment length polymorphism enables investigators to determine the frequency of this polymorphism in normal subjects and Alzheimer's disease patients.",
author = "Peacock, {M. L.} and Murman, {Daniel L} and Sima, {A. A.F.} and Warren, {J. T.} and Roses, {A. D.} and Fink, {J. K.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/ana.410350410",
language = "English (US)",
volume = "35",
pages = "432--438",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late‐onset Alzheimer's disease

AU - Peacock, M. L.

AU - Murman, Daniel L

AU - Sima, A. A.F.

AU - Warren, J. T.

AU - Roses, A. D.

AU - Fink, J. K.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Amyloid plaques in Alzheimer's disease contain β‐amyloid, encoded by portions of exons 16 and 17 of the amyloid precursor protein. The specific association of rare amyloid precursor protein mutations with some kindreds with early‐onset familial Alzheimer's disease suggests that specific abnormalities in amyloid precursor protein may contribute to the pathogenesis of Alzheimer's disease. Until now, there has been no evidence suggesting that amyloid precursor protein mutations could be involved in late‐onset or sporadic Alzheimer's disease. We used reverse transcription–polymerase chain reaction, denaturing gradient gel electrophoresis, and direct DNA sequencing to analyze amyloid precursor protein exons 16 and 17 from postmortem cerebellar samples from patients with histologically confirmed Alzheimer's disease and control subjects. We found a novel point mutation, substitution of cytosine for guanine, at nucleotide 2119 (amyloid precursor protein 770 messenger RNA transcript) in a patient with late‐onset Alzheimer's disease. This substitution deletes a BglII site and substitutes aspartate for glutamine at codon 665. Denaturing gradient gel electrophoresis analysis showed that this mutation was absent in 40 control subjects and 127 dementia patients. Whether this mutation is a rare but normal variant or contributes to the development of Alzheimer's disease is not known. The BglII restriction fragment length polymorphism enables investigators to determine the frequency of this polymorphism in normal subjects and Alzheimer's disease patients.

AB - Amyloid plaques in Alzheimer's disease contain β‐amyloid, encoded by portions of exons 16 and 17 of the amyloid precursor protein. The specific association of rare amyloid precursor protein mutations with some kindreds with early‐onset familial Alzheimer's disease suggests that specific abnormalities in amyloid precursor protein may contribute to the pathogenesis of Alzheimer's disease. Until now, there has been no evidence suggesting that amyloid precursor protein mutations could be involved in late‐onset or sporadic Alzheimer's disease. We used reverse transcription–polymerase chain reaction, denaturing gradient gel electrophoresis, and direct DNA sequencing to analyze amyloid precursor protein exons 16 and 17 from postmortem cerebellar samples from patients with histologically confirmed Alzheimer's disease and control subjects. We found a novel point mutation, substitution of cytosine for guanine, at nucleotide 2119 (amyloid precursor protein 770 messenger RNA transcript) in a patient with late‐onset Alzheimer's disease. This substitution deletes a BglII site and substitutes aspartate for glutamine at codon 665. Denaturing gradient gel electrophoresis analysis showed that this mutation was absent in 40 control subjects and 127 dementia patients. Whether this mutation is a rare but normal variant or contributes to the development of Alzheimer's disease is not known. The BglII restriction fragment length polymorphism enables investigators to determine the frequency of this polymorphism in normal subjects and Alzheimer's disease patients.

UR - http://www.scopus.com/inward/record.url?scp=0028226611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028226611&partnerID=8YFLogxK

U2 - 10.1002/ana.410350410

DO - 10.1002/ana.410350410

M3 - Article

VL - 35

SP - 432

EP - 438

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -